Preferred Label : brolucizumab;
MeSH hyponym : RTH-258; ESBA-1008;
UNII : XSZ53G39H5;
Origin ID : C000622091;
UMLS CUI : C4550124;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3601437/fr/beovu-brolucizumab-degenerescence-maculaire-liee-a-l-age-dmla-oedeme-maculaire-diabetique-omd
2025
France
evaluation of the transparency committee
macular degeneration
degeneration, nos
brolucizumab
diabetes mellitus
age, nos
macular degeneration
macule, nos
brolucizumab
macular edema
edema, nos
---
https://ansm.sante.fr/tableau-marr/brolucizumab
2023
false
false
false
France
French
risk management
brolucizumab
intravitreal injections
patients guideline
drug information
---
https://www.has-sante.fr/jcms/p_3456142/fr/beovu-brolucizumab-degenerescence-maculaire-liee-a-l-age-dmla
2023
false
false
false
France
Age-Related Macular Degeneration
treatment outcome
insurance, health, reimbursement
brolucizumab
Product containing precisely brolucizumab 120 milligram/1 milliliter conventional
release solution for injection (clinical drug)
Exudative age-related macular degeneration (disorder)
adult
antibodies, monoclonal, humanized
intravitreal injections
angiogenesis inhibitors
evaluation of the transparency committee
macular degeneration
brolucizumab
---
https://www.has-sante.fr/jcms/p_3375404/fr/beovu-brolucizumab
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
Product containing only brolucizumab in parenteral dose form (medicinal product form)
brolucizumab
intravitreal injections
adult
diabetes complications
vision disorders
evaluation of the transparency committee
brolucizumab
---
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or
Retinal Vascular Occlusion
https://recalls-rappels.canada.ca/fr/avis-rappel/beovu-brolucizumab-risque-inflammation-intraoculaire-vascularite-retinienne-etou
2022
false
false
false
Canada
French
English
pharmacovigilance note
brolucizumab
intravitreal injections
Product containing only brolucizumab in parenteral dose form (medicinal product form)
canada
wet macular degeneration
brolucizumab
retinal vasculitis
Retinal Vascular Occlusion
---
https://www.ema.europa.eu/en/medicines/human/EPAR/beovu
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug approval
europe
brolucizumab
brolucizumab
brolucizumab
product surveillance, postmarketing
adult
wet macular degeneration
intravitreal injections
aged
pregnancy
breast feeding
vascular endothelial growth factor a
angiogenesis inhibitors
angiogenesis inhibitors
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3224952/fr/beovu
2020
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
adult
wet macular degeneration
brolucizumab
brolucizumab
intravitreal injections
brolucizumab
angiogenesis inhibitors
angiogenesis inhibitors
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
---
